Tiantan Biological's first-half attributable net profit was about 299 million yuan, down 52.75% year on year

Earnings
โดย 北京商报·CN·Read original
Summary · why it matters

Tiantan Biological released its 2026 semi-annual report on the evening of August 28, reporting first-half attributable net profit of about 299 million yuan, down 52.75% year on year. In the same period, the company achieved operating revenue of about 2.595 billion yuan, down 16.56% year on year. Tiantan Biological is mainly engaged in the research, development, production and sales of blood products. The company said the change in operating revenue was mainly due to lower sales prices.

Impact on stocks 1

Others▼ · 1 stocks
© 2026 MarketDXNews